Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial — Michael Teufel (2017) | RDL Network
Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix
Discussion(0)
No comments yet. Be the first to comment.